Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases
Abstract A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointesti...
Gespeichert in:
| Veröffentlicht in: | Joint, bone, spine : revue du rhumatisme bone, spine : revue du rhumatisme, 2015-10, Vol.82, p.eS17-eS29 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | eS29 |
|---|---|
| container_issue | |
| container_start_page | eS17 |
| container_title | Joint, bone, spine : revue du rhumatisme |
| container_volume | 82 |
| creator | Avram, Annalina Duarte, Cátia Santos, Maria José Papagoras, Charalampos Ritis, Konstantinos Scarpioni, Roberto Schmidt, Wolfgang A Skendros, Panagiotis |
| description | Abstract A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described. |
| doi_str_mv | 10.1016/S1297-319X(15)30004-X |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1753008187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1297319X1530004X</els_id><sourcerecordid>1753008187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-ef68fad6d1e2e9ab4e961c00bbcf1b36e1c17c9c8fe96d19e73d546e8815ba733</originalsourceid><addsrcrecordid>eNqFkMFO3DAQhq0KVCj0EYpyhEOKJ4njhAMVWhW60kptaavuzXLsCRiyNvVkkfbt690FDlw42Za__x_Nx9gn4J-BQ336C4pW5iW082MQJyXnvMrn79g-SNnkshDVTro_I3vsA9FdYspC1O_ZXlHLxLXNPvs5tehH16-cv8l-6NGlVzbR3jqrR6SsDzGbznLIpv7WdW50wZ9lMyQKnrLLGBbZNeoh_xviYFOOkA7Zbq8Hwo9P5wH7c_n19-RbPvt-NZ1czHJTtdWYY183vba1BSyw1V2FbQ2G864zPXRljWBAmtY0ffqw0KIsrahqbBoQnZZlecCOt70PMfxbIo1q4cjgMGiPYUkKpEhWGmhkQsUWNTEQRezVQ3QLHVcKuFrbVBubaq1KgVAbm2qeckdPI5bdAu1L6llfAr5sAUyLPjqMikwyaNC6iGZUNrg3R5y_ajCD887o4R5XSHdhGX2yqEBRofi2ZN0BYtMwL_8D8XSZ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753008187</pqid></control><display><type>article</type><title>Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Avram, Annalina ; Duarte, Cátia ; Santos, Maria José ; Papagoras, Charalampos ; Ritis, Konstantinos ; Scarpioni, Roberto ; Schmidt, Wolfgang A ; Skendros, Panagiotis</creator><creatorcontrib>Avram, Annalina ; Duarte, Cátia ; Santos, Maria José ; Papagoras, Charalampos ; Ritis, Konstantinos ; Scarpioni, Roberto ; Schmidt, Wolfgang A ; Skendros, Panagiotis</creatorcontrib><description>Abstract A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.</description><identifier>ISSN: 1297-319X</identifier><identifier>EISSN: 1778-7254</identifier><identifier>DOI: 10.1016/S1297-319X(15)30004-X</identifier><identifier>PMID: 26717798</identifier><language>eng</language><publisher>France: Elsevier SAS</publisher><subject>Aged ; Anakinra ; Anti-IL-1β therapy ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Arthritis, Gouty - drug therapy ; Canakinumab ; Chronic Disease ; Colchicine - therapeutic use ; Comorbidity ; Febuxostat - therapeutic use ; Gout Suppressants - therapeutic use ; Gouty arthritis ; Humans ; Interleukin 1 Receptor Antagonist Protein - therapeutic use ; Interleukin-1 - antagonists & inhibitors ; Internal Medicine ; Male ; Patient Selection ; Prednisolone - therapeutic use ; Recurrence ; Rheumatology ; Tophaceous gout</subject><ispartof>Joint, bone, spine : revue du rhumatisme, 2015-10, Vol.82, p.eS17-eS29</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-ef68fad6d1e2e9ab4e961c00bbcf1b36e1c17c9c8fe96d19e73d546e8815ba733</citedby><cites>FETCH-LOGICAL-c494t-ef68fad6d1e2e9ab4e961c00bbcf1b36e1c17c9c8fe96d19e73d546e8815ba733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1297319X1530004X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26717798$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Avram, Annalina</creatorcontrib><creatorcontrib>Duarte, Cátia</creatorcontrib><creatorcontrib>Santos, Maria José</creatorcontrib><creatorcontrib>Papagoras, Charalampos</creatorcontrib><creatorcontrib>Ritis, Konstantinos</creatorcontrib><creatorcontrib>Scarpioni, Roberto</creatorcontrib><creatorcontrib>Schmidt, Wolfgang A</creatorcontrib><creatorcontrib>Skendros, Panagiotis</creatorcontrib><title>Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases</title><title>Joint, bone, spine : revue du rhumatisme</title><addtitle>Joint Bone Spine</addtitle><description>Abstract A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.</description><subject>Aged</subject><subject>Anakinra</subject><subject>Anti-IL-1β therapy</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Arthritis, Gouty - drug therapy</subject><subject>Canakinumab</subject><subject>Chronic Disease</subject><subject>Colchicine - therapeutic use</subject><subject>Comorbidity</subject><subject>Febuxostat - therapeutic use</subject><subject>Gout Suppressants - therapeutic use</subject><subject>Gouty arthritis</subject><subject>Humans</subject><subject>Interleukin 1 Receptor Antagonist Protein - therapeutic use</subject><subject>Interleukin-1 - antagonists & inhibitors</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Patient Selection</subject><subject>Prednisolone - therapeutic use</subject><subject>Recurrence</subject><subject>Rheumatology</subject><subject>Tophaceous gout</subject><issn>1297-319X</issn><issn>1778-7254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFO3DAQhq0KVCj0EYpyhEOKJ4njhAMVWhW60kptaavuzXLsCRiyNvVkkfbt690FDlw42Za__x_Nx9gn4J-BQ336C4pW5iW082MQJyXnvMrn79g-SNnkshDVTro_I3vsA9FdYspC1O_ZXlHLxLXNPvs5tehH16-cv8l-6NGlVzbR3jqrR6SsDzGbznLIpv7WdW50wZ9lMyQKnrLLGBbZNeoh_xviYFOOkA7Zbq8Hwo9P5wH7c_n19-RbPvt-NZ1czHJTtdWYY183vba1BSyw1V2FbQ2G864zPXRljWBAmtY0ffqw0KIsrahqbBoQnZZlecCOt70PMfxbIo1q4cjgMGiPYUkKpEhWGmhkQsUWNTEQRezVQ3QLHVcKuFrbVBubaq1KgVAbm2qeckdPI5bdAu1L6llfAr5sAUyLPjqMikwyaNC6iGZUNrg3R5y_ajCD887o4R5XSHdhGX2yqEBRofi2ZN0BYtMwL_8D8XSZ2w</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Avram, Annalina</creator><creator>Duarte, Cátia</creator><creator>Santos, Maria José</creator><creator>Papagoras, Charalampos</creator><creator>Ritis, Konstantinos</creator><creator>Scarpioni, Roberto</creator><creator>Schmidt, Wolfgang A</creator><creator>Skendros, Panagiotis</creator><general>Elsevier SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151001</creationdate><title>Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases</title><author>Avram, Annalina ; Duarte, Cátia ; Santos, Maria José ; Papagoras, Charalampos ; Ritis, Konstantinos ; Scarpioni, Roberto ; Schmidt, Wolfgang A ; Skendros, Panagiotis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-ef68fad6d1e2e9ab4e961c00bbcf1b36e1c17c9c8fe96d19e73d546e8815ba733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Anakinra</topic><topic>Anti-IL-1β therapy</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Arthritis, Gouty - drug therapy</topic><topic>Canakinumab</topic><topic>Chronic Disease</topic><topic>Colchicine - therapeutic use</topic><topic>Comorbidity</topic><topic>Febuxostat - therapeutic use</topic><topic>Gout Suppressants - therapeutic use</topic><topic>Gouty arthritis</topic><topic>Humans</topic><topic>Interleukin 1 Receptor Antagonist Protein - therapeutic use</topic><topic>Interleukin-1 - antagonists & inhibitors</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Patient Selection</topic><topic>Prednisolone - therapeutic use</topic><topic>Recurrence</topic><topic>Rheumatology</topic><topic>Tophaceous gout</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avram, Annalina</creatorcontrib><creatorcontrib>Duarte, Cátia</creatorcontrib><creatorcontrib>Santos, Maria José</creatorcontrib><creatorcontrib>Papagoras, Charalampos</creatorcontrib><creatorcontrib>Ritis, Konstantinos</creatorcontrib><creatorcontrib>Scarpioni, Roberto</creatorcontrib><creatorcontrib>Schmidt, Wolfgang A</creatorcontrib><creatorcontrib>Skendros, Panagiotis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Joint, bone, spine : revue du rhumatisme</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Avram, Annalina</au><au>Duarte, Cátia</au><au>Santos, Maria José</au><au>Papagoras, Charalampos</au><au>Ritis, Konstantinos</au><au>Scarpioni, Roberto</au><au>Schmidt, Wolfgang A</au><au>Skendros, Panagiotis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases</atitle><jtitle>Joint, bone, spine : revue du rhumatisme</jtitle><addtitle>Joint Bone Spine</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>82</volume><spage>eS17</spage><epage>eS29</epage><pages>eS17-eS29</pages><issn>1297-319X</issn><eissn>1778-7254</eissn><abstract>Abstract A subgroup of patients with gouty arthritis have a chronic recurring form that is particularly difficult to treat. Such patients experience repeated flares and often have abundant tophi. Many also have underlying comorbidities, such as renal impairment, cardiovascular disease, gastrointestinal disorders, obesity, and hypertension, which contraindicate the use of standard anti-inflammatory medications. Five patients with difficult to treat gouty arthritis who were either candidates and/or treated with anti-IL therapy are described.</abstract><cop>France</cop><pub>Elsevier SAS</pub><pmid>26717798</pmid><doi>10.1016/S1297-319X(15)30004-X</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1297-319X |
| ispartof | Joint, bone, spine : revue du rhumatisme, 2015-10, Vol.82, p.eS17-eS29 |
| issn | 1297-319X 1778-7254 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1753008187 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Anakinra Anti-IL-1β therapy Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Arthritis, Gouty - drug therapy Canakinumab Chronic Disease Colchicine - therapeutic use Comorbidity Febuxostat - therapeutic use Gout Suppressants - therapeutic use Gouty arthritis Humans Interleukin 1 Receptor Antagonist Protein - therapeutic use Interleukin-1 - antagonists & inhibitors Internal Medicine Male Patient Selection Prednisolone - therapeutic use Recurrence Rheumatology Tophaceous gout |
| title | Identifying Patient Candidates for IL-1 Inhibition: Lessons From Real-World Cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A19%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Identifying%20Patient%20Candidates%20for%20IL-1%20Inhibition:%20Lessons%20From%20Real-World%20Cases&rft.jtitle=Joint,%20bone,%20spine%20:%20revue%20du%20rhumatisme&rft.au=Avram,%20Annalina&rft.date=2015-10-01&rft.volume=82&rft.spage=eS17&rft.epage=eS29&rft.pages=eS17-eS29&rft.issn=1297-319X&rft.eissn=1778-7254&rft_id=info:doi/10.1016/S1297-319X(15)30004-X&rft_dat=%3Cproquest_cross%3E1753008187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1753008187&rft_id=info:pmid/26717798&rft_els_id=S1297319X1530004X&rfr_iscdi=true |